The etiology of keratoconus involves complex, multifactorial processes including both genetic and environmental contributions. No specific causative genes are catalogued in the current knowledge packet, and no defined Mendelian inheritance pattern is recorded. The classification of multiple numbered genetic subtypes within disease ontology systems suggests that heterogeneous underlying mechanisms may operate across affected individuals. Research publications in the domain include investigations into gene therapy and biomarker identification, indicating that the genetic architecture of the condition is an active area of scientific inquiry. The molecular mechanisms governing progressive corneal thinning and protrusion remain under investigation.

Diagnosis of keratoconus relies on clinical ophthalmic examination supplemented by corneal topographic and tomographic imaging, which detect the characteristic progressive thinning and anterior protrusion of the cornea. Corneal topography maps surface curvature irregularities, and tomography provides cross-sectional thickness data that characterize the extent of structural change. Longitudinal monitoring of topographic parameters documents progression. The current knowledge packet does not enumerate specific diagnostic criteria thresholds or newborn screening protocols for keratoconus.

Management of keratoconus addresses the progressive corneal deformation and associated visual impairment. An FDA-approved combination product, Photrexa Viscous (riboflavin ophthalmic solution administered in conjunction with ultraviolet A light, sponsored by Glaukos Corporation), carries approved orphan drug status for the treatment of keratoconus. Corneal collagen cross-linking — a procedure that employs riboflavin and ultraviolet A irradiation to stiffen corneal tissue and slow progression — is the subject of multiple ongoing clinical investigations. An additional agent, copper sulfate (sponsored by Glaukos Corporation), holds orphan drug designation and is under clinical investigation. Ongoing trials also examine novel optical contact lens designs and diagnostic imaging modalities relevant to disease management.

The clinical course of keratoconus is variable. In many individuals, progression stabilizes over time, particularly in adulthood, while others experience advancing corneal deformation that substantially compromises vision. Acute hydrops represents a recognized acute complication associated with the most severe forms of corneal protrusion. Significant visual impairment may ultimately necessitate advanced optical or surgical intervention in a subset of affected individuals. The extent of visual impact depends on the rate of disease progression and the degree of corneal structural change achieved before stabilization.

Keratoconus is an active area of clinical investigation, with numerous ongoing registered studies at ClinicalTrials.gov spanning a range of intervention types including drug therapy, medical devices, procedural interventions, and observational approaches. Active investigations encompass corneal cross-linking protocol optimization, novel optical aperture contact lens designs, biomechanical modeling of corneal tissue, longitudinal cohort characterization of clinical and subclinical disease, and advanced imaging assessment of ocular tissues. Research is conducted across academic medical centers and industry sponsors, with several investigations projected to extend through 2036. Intervention types represented include both academic-initiated studies and industry-sponsored trials.